MEDIFIRST SOLUTIONS PROVIDES UPDATE ON INTERNATIONAL SALES
April 10 2017 - 11:20AM
InvestorsHub NewsWire
Freehold, NJ -- April 10,
2017 -- InvestorsHub
NewsWire -- MEDIFIRST
SOLUTIONS, INC. (OTCQB:
MFST) (the “Company” or “Medifirst”) would like to update
shareholders regarding international sales for its FDA cleared
Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic
Device.
As previously announced, the Company presented its Time Machine
Laser at a conference in Morocco and at the Arab Health Conference
in Dubai. As a follow up to the various opportunities presented at
these conferences, Medifirst is conducting ongoing meetings in
Paris to complete and secure a definitive sales agreement.
Medifirst is pleased to announce that it entered into a letter of
intent with a Morocco based company, with offices in Paris, setting
forth an understanding of basic terms by which the Moroccan
distributor would agree to purchase a minimum of 100 units per
month. The 24 month agreement would include provisions to sell the
Company’s lasers in over 20 countries in Africa and the Mid-East.
Selling and distributing a medical device to foreign countries
involves many logistical concerns, including various medical device
registration requirements and various import and sales procedures
that are specific to each country before sales can commence.
Commented President Bruce J. Schoengood, “The process of completing
sales in the international arena involves many steps well beyond
the negotiation of basic terms. We are very pleased with the size
and scope of the potential sales in these countries and we continue
to work diligently to complete all the steps necessary.”
Although all parties are working
diligently to complete and address all the approvals and
filings required to initiate sales, at this time, we have not
entered into a definitive agreement as the prerequisite logistical
approvals have yet to be procured.
The Company is also engaged in ongoing negotiations with other
international medical distributors and on the US front Medifirst
has initiated its sales roll-out. Medifirst anticipates to
have further updates in the upcoming days and weeks regarding both
international and US sales. The company has also launched a
new website dedicated to The Time Machine Laser. Please visit
www.timemachinelaser.com for more
information.
About Medifirst Solutions,
Inc.
Medifirst Solutions, Inc., in response to its Premarket
Notification 510(k) submission for “The Time Machine” Series Laser,
received clearance from the U.S. Food and Drug Administration
(“FDA”) to market its infrared Time Machine TTML-8102000 Laser
Thermal Therapeutic Device. The Time Machine Series Lasers Model
TTML-8102000 - 810/830nm is intended for use in temporary relief of
minor muscle and joint pain, stiffness, minor arthritis pain,
muscle spasm, temporary increase in local blood circulation and
temporary relaxation of muscles by means of topical elevated tissue
temperature from infrared spectral emissions. Due to the
decrease of inflammation, patients have seen immediate aesthetic
improvements as well, such as in scar and incision healing. The
hand-held laser device, with pin-point accuracy, often gives
patients immediate results with no redness, swelling or down-time.
This unique laser device offers medical professionals an affordable
and effective tool to enhance their treatment protocols for their
patients and provide new revenue streams for their practice. The
laser division will be operated out of Medifirst's wholly owned
subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com and
www.timemachinelaser.com for more
information. Follow on Twitter @Medi_First and for Facebook visit
Medifirst Solutions.
Forward-Looking
Statements:
The statements in this press release that relate to the company's
expectations with regard to the future impact on the company's
results from new products in development are forward-looking
statements, and may involve risks and uncertainties, some of which
are beyond our control. Such risks and uncertainties are
described in greater detail in our filings with the U.S. Securities
and Exchange Commission. Since the information in this press
release may contain statements that involve risk and uncertainties
and are subject to change at any time, the company's actual results
may differ materially from expected results. We make no
commitment to disclose any subsequent revisions to forward-looking
statements. This release does not constitute an offer to sell or a
solicitation of offers to buy any securities of any entity.
Contact:
Investor Relations
Phone:
(732) 786-8044
Email:
admiin@medifirstsolutions.com
Website:
www.medifirstsolutions.com